All Stories

Cullinan pens $700M pact for BCMA bispecific to pair with another autoimmune T cell engager

Cullinan Therapeutics is paying $20 million upfront for a BCMAxCD3 bispecific T cell engager that the biotech plans to pair with its existing CD19 candidate

Jun 5, 2025 - 10:55
 0
Cullinan pens $700M pact for BCMA bispecific to pair with another autoimmune T cell engager
Cullinan Therapeutics is paying $20 million upfront for a BCMAxCD3 bispecific T cell engager that the biotech plans to pair with its existing CD19 candidate
Read More

Tags:

Previous Article

Organic Food And Beverages Market to Redefine the Future of the Industry

Next Article

Powerful new cannabis outstrips dangers of ‘Woodstock pot’

Related Posts

'Our data is resonating far more with the people that matter,' Bicara CEO says amid Merus race

'Our data is resonating far more with the people that m...

Jun 2, 2025  0

Bayer's Vividion secures rights to world's only clinical-stage WRN inhibitor from partner Roche

Bayer's Vividion secures rights to world's only clinica...

Jun 4, 2025  0

Fierce Biotech Layoff Tracker 2025: Keros cuts 70 jobs; iTeos winds down

Fierce Biotech Layoff Tracker 2025: Keros cuts 70 jobs;...

May 29, 2025  0